{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:40:33Z","timestamp":1791290433854,"version":"4.3.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increased risk of HIV acquisition during pregnancy and lactation among women is evident, necessitating their inclusion in the evaluation of new HIV prevention interventions. Pregnant and postpartum women specifically face challenges with oral PrEP associated with stigma, and the burden of using other tablets. Long-acting products may address challenges related to oral PrEP, however, there is limited data on product-specific preferences and acceptability among pregnant and lactating women.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a mixed-method study to assess the preferences and acceptability of long-acting PrEP modalities either under development or already established among pregnant and lactating women. We conducted quantitative surveys (<jats:italic>n<\/jats:italic>\u2009=\u2009434) and in-depth interviews (<jats:italic>n<\/jats:italic>\u2009=\u200980) in central and western Kenya. We used descriptive statistics and categorical variables to summarize frequencies and proportions. Inductive and deductive content analytic approaches were used for in-depth interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of respondents was 25\u00a0years (IQR 19.3\u201331.0). Majority were married (263\/434, 61%), had completed high school (222\/434, 51%), with no condoms use in the prior 3\u00a0months (348\/434, 80%). The most preferred PrEP formulations were injectable (251\/434, 57%) and implantable (175\/434, 40%) options. Participants who preferred injectable PrEP had 8.56 times higher odds of considering ease of use as a reason. (aOR\u2009=\u20098.56, 95% CI [3.81\u201320.48]) and 3.71 odds of choosing perceived discreteness (aOR\u2009=\u20093.71, 95% CI (1.57\u20139.97)) as their preference reasons. Participants who preferred Implant for HIV prevention had 2.31 odds of considering it due to perceived effectiveness in preventing HIV as a preference reason (aOR\u2009=\u20092.31, 95% CI (1.21\u20144.66)) and 2.53-fold of considering discreteness as a preference reason (aOR\u2009=\u20092.53, 95% CI (1.46\u20144.59)). From the in-depth interviews, women reported prospective acceptability due to the perceived convenience of LA products, perceived effectiveness, reduced cost, improved privacy, and reduced stigma. Women had concerns regarding the safety and efficacy of the products during pregnancy and lactation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Acceptability of LA products underscores the importance of considering the unique needs of pregnant and breastfeeding women in the development of future prevention interventions<jats:bold>.<\/jats:bold> Aligning preferences and needs would enhance the uptake and adherence outcomes of HIV prevention products.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-10414-z","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T09:10:46Z","timestamp":1736241046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preferences for and acceptability of long-acting HIV prevention products among pregnant and lactating women accessing health services in Kenya: a mixed method cross-sectional analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Vallery","family":"Ogello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mwangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Kwena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Thuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Makokha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmah","family":"Owidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Muteti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kiptinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly R.","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"10414_CR1","unstructured":"UNAIDS. Global HIV\/AIDS statistics. Available from: https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.unaids.org\/en\/resources\/fact-sheet&ved=2ahUKEwjCotqWjtuIAxVoQ6QEHahWA3A4ChAWegQIKBAB&usg=AOvVaw19l70Yl3-pfMospC4SgzMy. Cited 2024 Sep 19."},{"issue":"10","key":"10414_CR2","doi-asserted-by":"publisher","first-page":"e25818","DOI":"10.1002\/jia2.25818","volume":"24","author":"K Joshi","year":"2021","unstructured":"Joshi K, Lessler J, Olawore O, Loevinsohn G, Bushey S, Tobian AAR, et al. Declining HIV incidence in sub-Saharan Africa: a systematic review and meta-analysis of empiric data. J Int AIDS Soc. 2021;24(10):e25818.","journal-title":"J Int AIDS Soc"},{"key":"10414_CR3","unstructured":"UNAIDS . In Danger: UNAIDS Global AIDS Update 2022. 2022. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in-danger-global-aids-update. Cited 2024 Nov 7."},{"issue":"1","key":"10414_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/infdis\/jiy118","volume":"218","author":"LM Mofenson","year":"2018","unstructured":"Mofenson LM. Risk of HIV acquisition during pregnancy and postpartum: a call for action. J Infect Dis. 2018;218(1):1\u20134.","journal-title":"J Infect Dis"},{"issue":"1","key":"10414_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/infdis\/jiy113","volume":"218","author":"KA Thomson","year":"2018","unstructured":"Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis. 2018;218(1):16\u201325.","journal-title":"J Infect Dis"},{"issue":"2","key":"10414_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/QAI.0000000000001225","volume":"74","author":"J Kinuthia","year":"2017","unstructured":"Kinuthia J, Richardson BA, Drake AL, Matemo D, Unger JA, McClelland RS, et al. Sexual behavior and vaginal practices during pregnancy and postpartum: implications for HIV prevention strategies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;74(2):142\u20139.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"12","key":"10414_CR7","doi-asserted-by":"publisher","first-page":"e0209782","DOI":"10.1371\/journal.pone.0209782","volume":"13","author":"R Machekano","year":"2018","unstructured":"Machekano R, Tiam A, Kassaye S, Tukei V, Gill M, Mohai F, et al. HIV incidence among pregnant and postpartum women in a high prevalence setting. Lama JR, editor. PLoS ONE. 2018;13(12):e0209782.","journal-title":"PLoS ONE."},{"issue":"5","key":"10414_CR8","doi-asserted-by":"publisher","first-page":"e0197143","DOI":"10.1371\/journal.pone.0197143","volume":"13","author":"D Joseph Davey","year":"2018","unstructured":"Joseph Davey D, Farley E, Towriss C, Gomba Y, Bekker LG, Gorbach P, et al. Risk perception and sex behaviour in pregnancy and breastfeeding in high HIV prevalence settings: Programmatic implications for PrEP delivery. Yotebieng M, editor. PLoS ONE. 2018;13(5):e0197143.","journal-title":"PLoS ONE."},{"key":"10414_CR9","unstructured":"WHO, 2022. Mother to child transmission of HIV. 2022. Available from:\u00a0https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/prevention\/mother-to-child-transmission-of-hiv&ved=2ahUKEwiJ5eLBxqqFAxWAQ_EDHdyoCVsQFnoECA4QAw&usg=AOvVaw1ZSNOdGGXFDAXnnh9sY96D. Cited 2024 Apr 14."},{"key":"10414_CR10","unstructured":"UNAIDS. (n.d.). Start Free Stay Free AIDS Free - 2020 Progress Report. Available from:\u00a0https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/start-free-stay-free-aids-free-2020-progress-report_en.pd. Cited 2024 Apr 14."},{"key":"10414_CR11","doi-asserted-by":"publisher","first-page":"21295","DOI":"10.7448\/IAS.20.2.21295","volume":"20","author":"DL Seidman","year":"2017","unstructured":"Seidman DL, Weber S, Cohan D. Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach. J Int AIDS Soc. 2017;20:21295.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10414_CR12","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3018(19)30335-2","volume":"7","author":"J Kinuthia","year":"2020","unstructured":"Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. The Lancet HIV. 2020;7(1):e38-48.","journal-title":"The Lancet HIV"},{"issue":"6","key":"10414_CR13","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s10461-012-0317-8","volume":"17","author":"EM Van Der Elst","year":"2013","unstructured":"Van Der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162\u201372.","journal-title":"AIDS Behav"},{"issue":"9","key":"10414_CR14","doi-asserted-by":"publisher","first-page":"e26175","DOI":"10.1002\/jia2.26175","volume":"26","author":"L De Vos","year":"2023","unstructured":"De Vos L, Mudzingwa EK, Fynn L, Atujuna M, Mugore M, Gandhi M, et al. Factors that influence adolescent girls and young women\u2019s re-initiation or complete discontinuation from daily oral PrEP use: a qualitative study from Eastern Cape Province, South Africa. J Int AIDS Soc. 2023;26(9):e26175.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"10414_CR15","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1007\/s10461-022-03652-2","volume":"26","author":"I Beesham","year":"2022","unstructured":"Beesham I, Dovel K, Mashele N, Bekker LG, Gorbach P, Coates TJ, et al. Barriers to oral HIV pre-exposure prophylaxis (PrEP) adherence among pregnant and post-partum women from Cape Town. South Africa AIDS Behav. 2022;26(9):3079\u201387.","journal-title":"South Africa AIDS Behav"},{"issue":"20","key":"10414_CR16","first-page":"232595822110090","volume":"1","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Int Assoc Provid AIDS Care. 2021;1(20):232595822110090.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"12","key":"10414_CR17","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O\u2019Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973\u201383.","journal-title":"AIDS"},{"issue":"6","key":"10414_CR18","doi-asserted-by":"publisher","first-page":"e1003670","DOI":"10.1371\/journal.pmed.1003670","volume":"18","author":"C Celum","year":"2021","unstructured":"Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. Amico K, editor. PLoS Med. 2021;18(6):e1003670.","journal-title":"PLoS Med."},{"issue":"4","key":"10414_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/COH.0000000000000735","volume":"17","author":"C Flexner","year":"2022","unstructured":"Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):192\u20138.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"10414_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17(9):1227\u201338.","journal-title":"Expert Opin Drug Deliv"},{"issue":"10337","key":"10414_CR21","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. The Lancet. 2022;399(10337):1779\u201389.","journal-title":"The Lancet"},{"issue":"22","key":"10414_CR22","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med"},{"issue":"22","key":"10414_CR23","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, Van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"10414_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/COH.0000000000000599","volume":"15","author":"M Markowitz","year":"2020","unstructured":"Markowitz M, Grobler JA. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. Curr Opin HIV AIDS. 2020;15(1):27\u201332.","journal-title":"Curr Opin HIV AIDS"},{"issue":"S4","key":"10414_CR25","doi-asserted-by":"publisher","first-page":"e1003670","DOI":"10.1002\/jia2.25306","volume":"22","author":"R Eakle","year":"2019","unstructured":"Eakle R, Weatherburn P, Bourne A. Understanding user perspectives of and preferences for oral Pr EP for HIV prevention in the context of intervention scale-up: a synthesis of evidence from sub-Saharan Africa. J Intern AIDS Soc. 2019;22(S4):e1003670.","journal-title":"J Intern AIDS Soc"},{"key":"10414_CR26","doi-asserted-by":"crossref","unstructured":"Wara NJ, Mvududu R, Marwa MM, G\u00f3mez L, Mashele N, Orrell C, et al. Preferences and Acceptability for Long-Acting PrEP Agents Among Pregnant and Postpartum Women with Experience Using Daily Oral PrEP in South Africa and Kenya. HIV\/AIDS; 2022. Available from:\u00a0http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.10.29.22281701.\u00a0Cited 2024 Feb 26.","DOI":"10.1101\/2022.10.29.22281701"},{"issue":"11","key":"10414_CR27","doi-asserted-by":"publisher","first-page":"e0259779","DOI":"10.1371\/journal.pone.0259779","volume":"16","author":"M Sekhon","year":"2021","unstructured":"Sekhon M, Van Der Straten A, on behalf of the MTN-041\/MAMMA Study Team. Pregnant and breastfeeding women\u2019s prospective acceptability of two biomedical HIV prevention approaches in Sub Saharan Africa: A multisite qualitative analysis using the Theoretical Framework of Acceptability Dub\u00e9 K, editor. PLoS ONE. 2021;16(11):e0259779.","journal-title":"PLoS ONE."},{"key":"10414_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/IJWH.S185712","volume":"11","author":"MK Shapley-Quinn","year":"2019","unstructured":"Shapley-Quinn MK, Manenzhe K, Agot K, Minnis AM, Van Der Straten A. \u201cWe are not the same\u201d: African women\u2019s view of multipurpose prevention products in the TRIO clinical study. IJWH. 2019;11:97\u2013107.","journal-title":"IJWH"},{"issue":"3","key":"10414_CR29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s10461-023-04202-0","volume":"28","author":"KM Little","year":"2024","unstructured":"Little KM, Hanif H, Anderson SM, Clark MR, Gustafson K, Doncel GF. Preferences for long-acting PrEP products among women and girls: a quantitative survey and discrete choice experiment in Eswatini, Kenya, and South Africa. AIDS Behav. 2024;28(3):936\u201350.","journal-title":"AIDS Behav"},{"issue":"3","key":"10414_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/bjhp.12295","volume":"23","author":"M Sekhon","year":"2018","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of health care interventions: A theoretical framework and proposed research agenda. British J Health Psychol. 2018;23(3):519\u201331.","journal-title":"British J Health Psychol"},{"key":"10414_CR31","unstructured":"National AIDS Control Council. Kenya HIV Estimates Report. 2018. Nairobi, Kenya. Available from: Available at http:\/\/www.nsdcc.go.ke\/download\/kenya-aids-response-progress-report-2018\/."},{"issue":"4","key":"10414_CR32","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907.","journal-title":"Qual Quant"},{"issue":"9","key":"10414_CR33","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","volume":"24","author":"EE Tolley","year":"2020","unstructured":"Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, et al. Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS Behav. 2020;24(9):2520\u201331.","journal-title":"AIDS Behav"},{"issue":"1","key":"10414_CR34","first-page":"14","volume":"6","author":"MA Pourhoseingholi","year":"2013","unstructured":"Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013;6(1):14\u20137.","journal-title":"Gastroenterol Hepatol Bed Bench."},{"key":"10414_CR35","doi-asserted-by":"crossref","unstructured":"Tridane A, Raja A, Gaffar A, Lindquist T, Prabadi K. Android and ODK based data collection framework to aid in epidemiological analysis. OJPHI. 2014;5(3). Available from:\u00a0http:\/\/journals.uic.edu\/ojs\/index.php\/ojphi\/article\/view\/4996. Cited 2024 Sep 20.","DOI":"10.5210\/ojphi.v5i3.4996"},{"issue":"2","key":"10414_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1744-6155.2011.00283.x","volume":"16","author":"E Thomas","year":"2011","unstructured":"Thomas E, Magilvy JK. Qualitative rigor or research validity in qualitative research: scientific inquiry. J Spec Pediatr Nurs. 2011;16(2):151\u20135.","journal-title":"J Spec Pediatr Nurs"},{"issue":"7","key":"10414_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"12","key":"10414_CR38","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/S2352-3018(23)00261-8","volume":"10","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, et al. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. The Lancet HIV. 2023;10(12):e767\u201378.","journal-title":"The Lancet HIV"},{"issue":"3","key":"10414_CR39","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2352-3018(21)00280-0","volume":"9","author":"DL Joseph Davey","year":"2022","unstructured":"Joseph Davey DL, Bekker LG, Bukusi EA, Chi BH, Delany-Moretlwe S, Goga A, et al. Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap. The Lancet HIV. 2022;9(3):e214\u201322.","journal-title":"The Lancet HIV"},{"issue":"1","key":"10414_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-018-3463-4","volume":"18","author":"D Sidebottom","year":"2018","unstructured":"Sidebottom D, Ekstr\u00f6m AM, Str\u00f6mdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV \u2013 how can we improve uptake and adherence? BMC Infect Dis. 2018;18(1):581.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10414_CR41","doi-asserted-by":"publisher","first-page":"e1001608","DOI":"10.1371\/journal.pmed.1001608","volume":"11","author":"AL Drake","year":"2014","unstructured":"Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. Mofenson LM, editor. PLoS Med. 2014;11(2):e1001608.","journal-title":"PLoS Med."},{"issue":"1","key":"10414_CR42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12884-017-1421-6","volume":"17","author":"T Chetty","year":"2017","unstructured":"Chetty T, Vandormael A, Thorne C, Coutsoudis A. Incident HIV during pregnancy and early postpartum period: a population-based cohort study in a rural area in KwaZulu-Natal, South Africa. BMC Pregnancy Childbirth. 2017;17(1):248.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"2","key":"10414_CR43","doi-asserted-by":"publisher","first-page":"e13120","DOI":"10.1111\/mcn.13120","volume":"17","author":"VL Flax","year":"2021","unstructured":"Flax VL, Hawley I, Ryan J, Chitukuta M, Mathebula F, Nakalega R, et al. After their wives have delivered, a lot of men like going out: Perceptions of HIV transmission risk and support for HIV prevention methods during breastfeeding in sub-Saharan Africa. Matern Child Nutr. 2021;17(2):e13120.","journal-title":"Matern Child Nutr"},{"issue":"4","key":"10414_CR44","first-page":"185","volume":"2","author":"WA Ojieabu","year":"2011","unstructured":"Ojieabu WA, Femi-Oyewo MN, Eze UI. HIV\/AIDS knowledge, attitude and risk perception among pregnant women in a teaching hospital. Southwestern Nigeria J Basic Clin Pharm. 2011;2(4):185\u201398.","journal-title":"Southwestern Nigeria J Basic Clin Pharm"},{"issue":"11","key":"10414_CR45","doi-asserted-by":"publisher","first-page":"e0259779","DOI":"10.1371\/journal.pone.0259779","volume":"16","author":"M Sekhon","year":"2021","unstructured":"Sekhon M, Van Der Straten A, on behalf of the MTN-041\/MAMMA Study Team. Pregnant and breastfeeding women\u2019s prospective acceptability of two biomedical HIV prevention approaches in Sub Saharan Africa: A multisite qualitative analysis using the Theoretical Framework of Acceptability. Dub\u00e9 K, editor. PLoS ONE. 2021;16(11):e0259779.","journal-title":"PLoS ONE."},{"issue":"3","key":"10414_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/15562646211012296","volume":"16","author":"K Ngure","year":"2021","unstructured":"Ngure K, Trinidad SB, Beima-Sofie K, Kinuthia J, Matemo D, Kimemia G, et al. Perceived social influences on women\u2019s decisions to use medications not studied in pregnancy a qualitative ethical analysis of preexposure prophylaxis implementation research inKenya. J Empir Res Hum Res Ethics. 2021;16(3):225\u201337.","journal-title":"J Empir Res Hum Res Ethics."},{"key":"10414_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2021.10.001","volume":"106","author":"K Ridgeway","year":"2022","unstructured":"Ridgeway K, Montgomery ET, Smith K, Torjesen K, Van Der Straten A, Achilles SL, et al. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. Contraception. 2022;106:16\u201333.","journal-title":"Contraception"},{"issue":"8","key":"10414_CR48","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, Van Der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159\u201367.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10414-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10414-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10414-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T10:03:32Z","timestamp":1736244212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10414-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10414"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10414-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Institutional Review Board at Jomo Kenyatta University of Science and Technology (JKUAT-ERC) (JKU\/2\/4\/896B) and was conducted in compliance with ethical principles outlined in the declaration of Helsinki. All participants provided written informed consent. Participants were only identified by unique codes during data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}